Navidea Biopharmaceuticals
Columbus
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) focuses on the development of innovative immunodiagnostic agents and immunotherapeutics to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Patients and physicians, aspire to provide innovative immunodiagnostic agents and therapies to improve patient care for serious diseases. For investors, they aim to deliver superior growth through their focus on developing their innovative Manocept™ platform and driving efficient business processes. For their employees, they provide a culture that focuses on the direct contributions their efforts make for the patients they serve and an innovative development environment for new breakthrough products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $133.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2023)
- Ticker: nysemkt:NAVB
- Website: navidea.com
- Phone: 614-822-2373
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/navidea-biopharmaceuticals-166041 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.